Aldeyra has resubmitted its new drug application for reproxalap, an investigational dry eye treatment, which contained new ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Investing.com -- Dyne Therapeutics, Inc. (Nasdaq:DYN) stock fell 23% after the company announced an updated plan for obtaining U.S. Accelerated Approval for DYNE-101 in myotonic dystrophy type 1 (DM1) ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

Roche entered into a Licensing, Development, and Commercialisation agreement with Prothena in December 2013 to develop and ...

The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

Experts reassess endpoints, patient selection, targets, and timing for the development of successful immune-based treatments ...

New data from the POETYK PsA-Phase III trial, presented at the 2025 EULAR Congress, demonstrate that Bristol Myers Squibb’s Sotyktu (deucravacitinib) significantly improves joint and skin symptoms in ...

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

This is a developing news story. Please check back soon for updates. The FDA granted VG801 rare pediatric disease designation ...

Researchers identified a biomarker that may predict the recurrence of a diabetic foot ulcer that had previously healed. In a study published in Diabetes Care, researchers measured transepidermal water ...

In a call hosted today, June 9, 2025, PolyPid Ltd. unveiled highly successful topline results from its SHIELD II Phase 3 ...